• Apellis Pharmaceuticals Inc APLS.OQ reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -73 cents. The mean expectation of twenty one analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -61 cents to -24 cents per share.

• Revenue rose 45.2% to $212.53 million from a year ago; analysts expected $198.35 million.

• Apellis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $36.35 million.

• Apellis Pharmaceuticals Inc shares had fallen by 18.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $46.00

This summary was machine generated from LSEG data February 28 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)